Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$16.8K Sell
928
-376
-29% -$8.04K ﹤0.01% 1271
2026
Q1
$26.6K Buy
1,304
+376
+41% +$8.36K ﹤0.01% 877
2025
Q4
$18K Sell
928
-4
-0.4% -$84 ﹤0.01% 992
2025
Q3
$24.1K Buy
932
+928
+23,200% +$21.7K ﹤0.01% 702
2025
Q2
$89 Hold
4
﹤0.01% 1093
2025
Q1
$51 Hold
4
﹤0.01% 708
2024
Q4
$69 Hold
4
﹤0.01% 709
2024
Q3
$90 Hold
4
﹤0.01% 723
2024
Q2
$99 Hold
4
﹤0.01% 723
2024
Q1
$132 Hold
4
﹤0.01% 832
2023
Q4
$147 Hold
4
﹤0.01% 735
2023
Q3
$147 Buy
+4
New +$159 ﹤0.01% 732

Other funds holding ADNT

Salomon & Ludwin's ADNT Position: Q2 2026 in Review

Salomon & Ludwin reduced its Adient (ADNT) stake by 29% in Q2 2026, selling an estimated $8.04K and leaving 928 shares worth $16.8K. The position accounts for ﹤0.01% of the portfolio, ranked #1271.

Salomon & Ludwin first reported a position in ADNT in Q3 2023 and has held it in 12 quarters since. The position peaked at $26.6K in Q1 2026. 313 funds tracked by Wall St. Rank hold ADNT as of Q2 2026.

  • Salomon & Ludwin held 928 shares of Adient worth $16.8K as of Q2 2026.
  • Salomon & Ludwin sold 376 Adient shares in Q2 2026, an estimated $8.04K.
  • Adient made up ﹤0.01% of Salomon & Ludwin's portfolio in Q2 2026, its #1271 holding.
  • Salomon & Ludwin first reported a position in Adient in Q3 2023 and has held it in 12 quarters since.
  • Salomon & Ludwin's Adient position peaked at $26.6K in Q1 2026.
  • 313 funds tracked by Wall St. Rank held Adient as of Q2 2026.

Based on Salomon & Ludwin's 13F filing for Q2 2026, filed 7 Aug 2026.